Clinical Trial Update: Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing intravenous ferric carboxymaltose (FCM) to standard of care for iron deficiency anemia in heavy uterine bleeding and postpartum p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• FCM (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2015-05-29